Structure Therapeutics’ (GPCR) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report released on Friday, Benzinga reports. They currently have a $65.00 target price on the stock.

Separately, Lifesci Capital reaffirmed an outperform rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $85.71.

Structure Therapeutics Trading Up 1.1 %

Structure Therapeutics stock traded up $0.45 during mid-day trading on Friday, reaching $39.74. The company’s stock had a trading volume of 639,666 shares, compared to its average volume of 570,066. The firm has a market cap of $1.85 billion and a price-to-earnings ratio of -50.19. The business has a 50 day moving average price of $39.34 and a 200-day moving average price of $46.69. Structure Therapeutics has a twelve month low of $21.79 and a twelve month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. On average, equities analysts expect that Structure Therapeutics will post -0.98 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc increased its holdings in shares of Structure Therapeutics by 109.3% in the 3rd quarter. TD Asset Management Inc now owns 152,176 shares of the company’s stock valued at $7,673,000 after purchasing an additional 79,467 shares during the period. Jennison Associates LLC increased its holdings in shares of Structure Therapeutics by 5.2% in the 3rd quarter. Jennison Associates LLC now owns 420,479 shares of the company’s stock valued at $21,201,000 after purchasing an additional 20,699 shares during the period. Platinum Investment Management Ltd. increased its holdings in shares of Structure Therapeutics by 249.7% in the 3rd quarter. Platinum Investment Management Ltd. now owns 52,461 shares of the company’s stock valued at $2,645,000 after purchasing an additional 37,461 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Structure Therapeutics in the 3rd quarter valued at about $7,611,000. Finally, Picton Mahoney Asset Management bought a new stake in shares of Structure Therapeutics in the 3rd quarter valued at approximately $116,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.